Latest / Moving Medicine Forward
The Future is Cellular: Optieum Bio’s Next-Generation Approach to Glioblastoma
Glioblastoma remains one of the most aggressive and difficult-to-treat forms of brain cancer, with recurrence posing a significant challenge for patients and researchers alike. In this episode of Moving Medicine Forward, Jeremy Schrand sits down with Moya Daniels, Vice President, Head of Regulatory and QA at Optieum Biotechnologies, to discuss the company's novel CAR-T cell therapy program, OPTF01, and its potential to transform treatment for recurrent glioblastoma.
Moya shares insights into the science behind targeting both tumor cells and the tumor microenvironment, the evolving landscape…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.